Best Continuous Glucose Monitors (CGM) 2026: Dexcom vs Libre vs Stelo Compared
CGM technology is transforming diabetes management. We compare the top continuous glucose monitors of 2026 — Dexcom G7, FreeStyle Libre 3, and the new OTC options — on accuracy, cost, and usability.
Blood Glucose Monitoring System
Accurate, easy-to-use glucose meter for daily diabetes management.
As an Amazon Associate we earn from qualifying purchases.
Best Continuous Glucose Monitors 2026
Continuous glucose monitors (CGMs) are arguably the most transformative technology available for diabetes management in 2025–2026. Unlike traditional fingerstick testing, which gives a single glucose reading at one moment in time, a CGM provides glucose readings every 1–5 minutes, 24 hours a day — including while you sleep. This data reveals patterns that fingerstick testing entirely misses: nocturnal hypoglycemia, post-meal spikes from specific foods, and the glucose impact of exercise, stress, and poor sleep.
The CGM market has expanded dramatically in recent years, with over-the-counter options now available in the United States for the first time, making this technology accessible without a prescription for many users.
1. Dexcom G7 — Best Overall for Type 1 and Insulin-Dependent Type 2
The Dexcom G7 is the most accurate CGM available as of 2026. The sensor sits on the upper arm and communicates directly with iPhone and Android smartphones via Bluetooth, eliminating the need for a separate receiver. The G7 features a 30-minute warmup period (down from 2 hours on previous models), a 10-day sensor life, and integration with virtually every major insulin pump through Dexcom's CLARITY platform.
- MARD (accuracy): 8.2% — best in class
- Sensor life: 10 days
- Warmup time: 30 minutes
- Alerts: customizable high/low glucose alarms with urgent low alarm at 55 mg/dL
- Cost without insurance: approximately $350–$400/month for sensors
- Best for: type 1 diabetes, type 2 on insulin, anyone who needs the highest accuracy available
2. Abbott FreeStyle Libre 3 — Best Value for Type 2 Diabetes
The FreeStyle Libre 3 is the world's smallest and thinnest CGM sensor, worn on the upper arm. Unlike the Libre 2, the Libre 3 provides real-time glucose readings directly to a smartphone without requiring a scan. Sensor life is 14 days — the longest of any major CGM. Cost is approximately 30% lower than the Dexcom G7, making it the most popular CGM for type 2 diabetes management.
- MARD (accuracy): 9.2%
- Sensor life: 14 days
- Real-time readings: yes (automatic every minute)
- Cost without insurance: approximately $130–$160/month
- Best for: type 2 diabetes, cost-conscious users, first-time CGM users
3. Dexcom Stelo — Best Over-the-Counter Option
The Dexcom Stelo became the first FDA-cleared OTC CGM in the United States in 2024, designed specifically for adults with type 2 diabetes not on insulin. It requires no prescription and is available at major pharmacy retailers. The Stelo uses the same Dexcom accuracy platform but removes the urgent low alert (as severe hypoglycemia is rare in non-insulin users) and is priced at approximately $99 per month for two 15-day sensors.
- Prescription required: No — available OTC
- Sensor life: 15 days
- Cost: approximately $99/month (2 sensors)
- Best for: type 2 not on insulin, people new to CGM who want to try without a prescription
4. Abbott Lingo — Best for Wellness and Prediabetes
Abbott's Lingo (also OTC) targets the broader wellness market including people with prediabetes. It uses the FreeStyle Libre sensor platform, provides lifestyle coaching through its app, and costs approximately $49 for a 2-week sensor — the most affordable entry into CGM technology.
Which CGM Should You Choose?
For type 1 diabetes or type 2 on insulin: Dexcom G7 for maximum accuracy and pump integration. For type 2 on non-insulin medications: FreeStyle Libre 3 for best value, or Dexcom Stelo for OTC convenience. For prediabetes or general wellness: Abbott Lingo or Dexcom Stelo. Always verify insurance coverage before purchasing — most commercial insurance and Medicare cover CGMs for insulin-using diabetics.
Studies show CGM use reduces HbA1c by an average of 0.9–1.0% in type 2 diabetes, even without insulin use. The behavioral data provided by real-time glucose monitoring changes eating decisions in ways that no other tool can match.